T cells are key components of the tumour microenvironment (TME), and their therapeutic manipulation with immune checkpoint inhibitors or upon adoptive cell transfer has produced recent breakthroughs in the treatment of cancer 1, 2 . While most T cell research and clinical application has centred on αβ T cells -that is, T cells expressing a lineage-specific αβ T cell receptor (TCR) -γδ TCR-expressing T cells are also important players in cancer immunity 3 . γδ T cells share many qualities with their αβ T cell counterparts, such as cytotoxic effector functions and pro-inflammatory cytokine production, but one major difference between γδ T cells and αβ T cells is their relative dependence on major histocompatibility complex (MHC) molecules. The γδ TCR does not bind MHC molecules, and antigen recognition by γδ T cells has remained elusive, as recently discussed elsewhere 4, 5 . This distinction from αβ T cells, coupled with the relatively low numbers of γδ T cells in mammals, has slowed down progress on understanding their role in tumorigenesis. However, the last few years have seen major advances in our knowledge of cancer-associated γδ T cell biology ( Fig. 1 ): uncovering their powerful influence on tumours and other immune cells, highlighting their multifaceted role as both anti-and pro-tumour mediators, and unravelling the individual contributions of γδ T cell subsets to cancer progression.
T cells are key components of the tumour microenvironment (TME), and their therapeutic manipulation with immune checkpoint inhibitors or upon adoptive cell transfer has produced recent breakthroughs in the treatment of cancer 1, 2 . While most T cell research and clinical application has centred on αβ T cells -that is, T cells expressing a lineage-specific αβ T cell receptor (TCR) -γδ TCR-expressing T cells are also important players in cancer immunity 3 . γδ T cells share many qualities with their αβ T cell counterparts, such as cytotoxic effector functions and pro-inflammatory cytokine production, but one major difference between γδ T cells and αβ T cells is their relative dependence on major histocompatibility complex (MHC) molecules. The γδ TCR does not bind MHC molecules, and antigen recognition by γδ T cells has remained elusive, as recently discussed elsewhere 4, 5 . This distinction from αβ T cells, coupled with the relatively low numbers of γδ T cells in mammals, has slowed down progress on understanding their role in tumorigenesis. However, the last few years have seen major advances in our knowledge of cancer-associated γδ T cell biology ( Fig. 1) : uncovering their powerful influence on tumours and other immune cells, highlighting their multifaceted role as both anti-and pro-tumour mediators, and unravelling the individual contributions of γδ T cell subsets to cancer progression.
An intrinsic difficulty in γδ T cell research is the evolutionary divergence of TCR genes between humans and mice, where most preclinical work is performed. In particular, the major γδ T cell subsets in humans do not have orthologues in mice 6 . Moreover, the most relevant mouse γδ T cell subsets are defined by the TCR Vγ chain usage (that is, Vγ1-7), in contrast with Vδ-based subsets in humans (that is, Vδ1-3) 3 . Despite this clear discrepancy, functionally analogous γδ T cell populations -that is, with similar effector functions and (patho) physiological roles -can be found in mice and humans, which has contributed decisively to our increased understanding of the place occupied by γδ T cells in immunity. Along these lines, an important recent finding was the conserved role of butyrophilin family members in homeostatic interactions with functionally equivalent subsets of mouse and human intestinal γδ T cells 7 . In this Review we elaborate on the basic biological behaviour and therapeutic potential of γδ T cells in cancer, from their functional properties and regulation in the TME to the design of new γδ T cell-based approaches for cancer immunotherapy.
Antitumour functions of γδ T cells Direct tumour cell targeting by γδ T cells. The seminal study that established an antitumour role for γδ T cells in mice came from the Hayday laboratory and demonstrated that these cells control the development and growth of transplantable squamous cell carcinomas, as well as methylcholanthrene (MCA)-induced or dimethylbenz [a] anthracene (DMBA)-induced cutaneous tumours 8 . The strong antitumour function of mouse γδ T cells in the MCA cancer model was corroborated by other groups 9 and extended to models of spontaneous B cell lymphomas 10 , prostate cancer 11 and the widely used B16 melanoma model 9, 12, 13 . γδ T cell recognition of γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer cancer cells relies on the engagement of their TCR and/or natural killer cell receptors (NKRs) 14 . In mice, skin exposure to carcinogens leads to expression of the stress ligands RAE-1 and H60 by keratinocytes that bind the natural killer group 2D (NKG2D) receptor expressed on skin-resident Vγ5 + T cells (also called dendritic epidermal T cells (DETCs)) 8 . Indeed, acute changes in NKG2D ligand expression in the epidermis induce both morphological changes 15, 16 and interleukin-13 (IL-13) expression 17 in Vγ5 + T cells, to counteract carcinogenesis in vivo. The mechanism by which γδ T cell-derived IL-13 protects against tumour formation in the DMBA cancer model is not entirely clear. IL-13 activates keratinocytes via the IL-13 receptor (IL-13Rα1) to produce various cytokines and mediates the migration of keratinocytes through the epidermis 17 , but whether these effects explain the antitumour functions has yet to be formally established.
Recent studies have shown that inhibition of mTOR signalling using rapamycin increases NKG2D expression on ex vivo-expanded mouse Vγ4 + T cells, as well as enhancing their cytotoxicity to various cancer cell lines 18 . Human γδ T cells also recognize transformed cells through NKG2D 14, 19 . Tumour cells in both solid and haematological malignancies frequently express the human orthologues of RAE-1, MHC class I polypeptide-related sequence A (MICA) and MICB, as well as members of the UL16 binding protein (ULBP) family (ULBP1-6) that also activate NKG2D-expressing Vδ1 + cells 20 and Vδ2 + cells 21, 22 . Other NKRs -such as DNAM-1, NKp30 and NKp44, which can be expressed by γδ T cells and play a role in the recognition of cancer cells -are reviewed elsewhere 14, 23 . The mechanisms by which γδ T cells kill cancer cells are similar to those of conventional cytotoxic T cells (Fig. 2) . In fact, the engagement of NKG2D activates cytolytic responses in human γδ T cells 19 , which are mediated by the granule exocytosis pathway through secretion of the pore-forming molecule perforin and the pro-apoptotic protease granzyme B. In mouse studies, γδ T cells and CD8 + T cells infiltrating B16 melanoma lesions express perforin and granzyme B to the same degree 12 . However, specific subsets of γδ T cells are more prone to cancer cell killing than other subpopulations. In vitro-expanded splenic Vγ4 + cells express higher levels of perforin and induce greater mouse YAC-1 T cell lymphoma and B16 melanoma cell death than do Vγ1 + cells 13 . Similarly, human γδ T cells employ the granule exocytosis pathway to kill various cancer cell types in vitro, such as renal cell carcinoma cells 24 , squamous cell carcinoma cells 25 , colorectal carcinoma cells 25, 26 , transformed kidney fibroblasts 25 and chronic myeloid leukaemia (CML) cells 27 . Beyond the perforin-granzyme axis, human Vγ9Vδ2 T cells also induce in vitro killing of CML cells 27 and lung cancer cells 28 through the expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). In addition, FAS ligand, another member of the TNF family that induces apoptosis in target cells, mediates human γδ T cell killing of FAS receptor-expressing osteosarcoma cell lines in vitro 29 . Human γδ T cells also use antibody-dependent cellular cytotoxicity (ADCC), which is a cell death-inducing mechanism by which immune cells that express Fc receptors recognize antibodies bound to a target cell. Indeed, CD16 (also known as Fcγ receptor III) expression by circulating T lymphocytes is mainly attributed to γδ T cells 30 . Upon activation, Vγ9Vδ2 T cells upregulate CD16 and can induce ADCC on target cells following treatment with antibodies, such as the monoclonal antibody trastuzumab that targets human epidermal growth factor receptor 2 (HER2; also known as ERBB2) 31, 32 , the B lymphocyte antigen CD20-specific monoclonal antibody rituximab 31, 33 , bispecific antibodies that bind the TCR complex and HER2 (reF. 34 ), or even B lymphocyte antigen CD19-specific triplebodies 35 . Interestingly, this category of killing seems specific to Vγ9Vδ2 T cells, as their Vδ1 + T cell counterparts utilize antibody-independent mechanismswhich may include increased production of interferon-γ (IFNγ) and granzyme B -to induce neuroblastoma cell death in vitro 36 . However, ADCC may not be the only outcome of CD16 activation, as IgG-opsonized human cytomegalovirus induces IFNγ production by Vδ2 + T cells in a CD16-dependent manner, but the importance of this mechanism remains unknown for antitumour responses 30 . 
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Indirect effects οf γδ T cells on antitumour immunity. γδ T cells also influence antitumour immunity by orchestrating downstream immune responses (Fig. 2) . In B16 melanoma, they express IFNγ in the tumour bed to amplify IFNγ production in αβ T cells 9 and induce MHC-I expression on tumour cells 37 , thereby increasing the potency of cytotoxic T cells and potentiating the recognition of cancer cells. Likewise, human blood-derived and gastric tumour-derived γδ T cells stimulate αβ T cell activation and proliferation -an effect achieved by the antigen-presenting cell properties of Vγ9Vδ2 T cells [38] [39] [40] [41] [42] . In fact, this subset not only expresses levels of antigen presentation molecules and co-stimulatory molecules similar to those of standard antigen-presenting cells 38 , they are also functionally equivalent to mature dendritic cells (DCs) in their ability to induce peptide-specific T cell activation and expansion 39 . These antigen-presenting cell functions can be further enhanced by tumour-reactive mono clonal antibodies 41 . The impact of γδ T cells on antitumour immunity is not limited to the promotion of αβ T cell responses, since activated human γδ T cells can stimulate NK cell cytotoxicity via co-stimulation of CD137 (also known as 4-1BB) 43 . However, it should be noted 44 . These data suggest that the effects of γδ T cells on antitumour immunity are context-dependent and may be modulated by zoledronate.
Another established function of mouse γδ T cells in immunology is the provision of help towards immunoglobulin class switching, germinal centre formation, production of autoantibodies and shaping of pre-immune peripheral B cell populations [45] [46] [47] . These data may also extend to human γδ T cells, as Vγ9Vδ2 T cells stimulated in vitro with IL-21 and (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) -a microbial metabolite -increased the production of the B cell chemoattractant CXC-chemokine ligand 13 (CXCL13), increasing the T cells' potential to influence B cells 48 . A few studies have begun to elucidate the relevance of this γδ T cell function in antitumour responses. In a mouse model of epidermal hyperplasia driven by the loss of Notch1 in keratinocytes that express an artificial antigen, β-galactosidase, the induction of skin hyperplasia results in increased production of β-galactosidase-specific IgG, which is dependent on γδ T cells 49 . However, the impact of these tumour-specific, γδ T cell-dependent antibodies on cancer progression in this model is unknown. More recently, a protective response by tumour-specific antibodies that are induced by γδ T cells was shown in a model of DMBA-driven cutaneous tumorigenesis 50 , where the antitumour functions of NKG2D-expressing Vγ5 + T cells were previously established 8, 15 . In this report, topical exposure to DMBA leads to Vγ5 + T cell-dependent B cell class switching to IgE. The accumulation of autoreactive IgE protects against carcinogenesis in an Fcε receptor I-dependent manner, indicating that γδ T cells play an important role in tumour protection by helping B cells to undergo class switching 50 .
In mice, γδ T cells can play a beneficial role in chemotherapy and targeted therapy response. Namely, γδ T cells were required for the antiproliferative effects of doxorubicin on subcutaneously injected mouse AT3 mammary cells 51 and mouse MCA205 fibrosarcoma cells 51, 52 . The mechanism proposed for this antitumour benefit involves IL-17A-producing γδ T cells that control the influx and activity of IFNγ-expressing CD8 + T cells 52 . Similarly, in a cKIT-mutated mouse model of gastrointestinal stromal tumours (GIST), γδ T cells mediated antitumour immunity and limited tumour progression following cKIT inhibitor therapy with imatinib. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing γδ T cells regulated the infiltration of CD103 + DCs (and subsequently CD8 + T cells), under the direction of macrophages producing IL-1β 53 . Interestingly, γδ T cells co-expressed GM-CSF and IL-17A in the GIST mouse model, even though the role of IL-17A was not tested. These data stand in contrast to the large body of literature on the pro-tumour functions of IL-17A-producing γδ T cells (discussed in the next section), suggesting that chemotherapy and targeted therapy in some scenarios may alter the natural functions of IL-17A-producing γδ T cells.
Pro-tumour functions of γδ T cells
Much of what we know about the pro-tumorigenic roles of γδ T cells stems from their ability to produce IL-17A (Box 1). Various studies have shown that expression of IL-17 (used hereafter to denote IL-17A, for simplification) is increased by γδ T cells in tumours formed following the injection of cancer cell lines subcutaneously, orthotopically or intravenously in mice [54] [55] [56] [57] [58] [59] [60] [61] , and that implanting these same cell lines into IL-17 knockout mice results in reduced tumour growth in models of breast cancer 61 , fibrosarcoma 54, 57 , hepatocellular carcinoma 59 , lung cancer 55, 58 , melanoma 55, 58 and ovarian cancer 60 . IL-17-producing γδ T cells are also increased in autochthonous genetically engineered models of cancer, such as the Mist1-Cre ERT2 ;Kras G12D model of early pancreatic cancer 62 , colorectal cancer models driven by loss of the tumour suppressor adenomatous polyposis coli (Apc) 63, 64 54, 68 or to upregulate adhesion molecules and endothelial cell permeability that promotes metastases at secondary sites 58 . In mice bearing mouse ID8 ovarian cancer cells, the expansion of IL-17-producing γδ T cells promoted the recruitment of pro-angiogenic macrophages to tumours and Box 1 | Phenotypic markers of effector γδ T cell subsets γδ T cell differentiation has been mostly dissected in the C57BL/6 mouse, where the two main effector cytokines implicated in γδ T cell responses are interferon-γ (IFNγ) and interleukin-17A (IL-17A). These are mostly expressed by distinct subsets segregated on the basis of markers such as CD27, CD122 and CD45RB (a splice variant of CD45), which are expressed on IFNγ + γδ T cells, and CC-chemokine receptor 6 (CCR6) and the scavenger receptor SCART-2, which are found on IL-17A + γδ T cells. IL-17 producers also express higher levels of CD44, whereas NK1.1 marks IFNγ hi γδ T cells 161 . Moreover, effector γδ T cell differentiation varies across thymic developmental waves characterized by T cell receptor Vγ chain usage as result of V(D)J recombination; for example, fetal-derived Vγ6 + γδ T cells produce IL-17A but not IFNγ, whereas perinatal vγ1 + γδ T cells are biased towards IFNγ expression. Importantly, most of the accumulated evidence suggests that, whereas γδ T cells that make IFNγ participate in antitumour responses, IL-17A production underlies tumour-promoting functions in various tumour mouse models 3 . In humans, the developmental and phenotypic segregation between IL-17A-versus IFNγ-producing γδ T cells is much less straightforward. For example, IL-17A producers have been found to be mostly Vδ1 + and to lack CD27 expression, but the majority of cells with this phenotype are actually IFNγ producers 72, 77 . Thus, unlike in the mouse, the definition of effector γδ T cell subsets in humans must always rely on cytokine production itself (as assessed by intracellular staining).
Aminobisphosphonate
A drug type that derives from bisphosphonates and is commonly used in bonerelated disorders to avoid excessive bone resorption.
Immunoglobulin class switching
Mechanism by which B cells change the isotype of immunoglobulin produced, altering its effector function.
Germinal centre
A site within the spleen and lymph nodes where B cells proliferate, differentiate and perform immunoglobulin class switching.
V(D)J recombination
Also known as somatic recombination. The somatic rearrangement of variable (V), diversity (D) and joining (J) regions of the genes that encode antigen receptors, leading to repertoire diversity of both T cell and B cell receptors.
NatUre revIews | CanCer initiated an angiogenic switch 60 . There is also a strong reciprocal link between IL-17-producing γδ T cells and neutrophils. These two cell types influence each other by γδ T cell-driven, granulocyte colony-stimulating factor (G-CSF)-mediated expansion and polarization of neutrophils towards an immunosuppressive phenotype 56, 59, 65 , as well as neutrophil-mediated upregulation of IL-17 expression in γδ T cells 59 . These mechanisms support tumour growth and metastasis by dampening antitumour immunity in mouse models of liver 59 and breast 65 cancer. More recently, it has been shown in lung tumour-bearing Kras G12D ;Trp53 F/F mice that microbiota-triggered IL-17-producing γδ T cells promote cancer progression 67 . Neutralization of IL-17 in these tumour-bearing mice reduces G-CSF levels as well as neutrophil infiltration into tumours, which is a mechanism analogous to the γδ T cell-IL-17-G-CSFneutrophil axis that promotes breast cancer lung metastasis 65 . IL-17-producing γδ T cells are rarely found in healthy individuals 70, 71 , but these cells accumulate in disease settings, such as meningitis 71 and cancer. Thus, these cells infiltrate into human tumours from patients with gall-bladder 72 , breast 73 , colon 74, 75 , lung 76 , ovarian 73 and cervical 68 cancer, as well as cutaneous squamous cell carcinoma 77 . A few of these studies have shown a preference for IL-17 among Vδ1 + T cells 72, 77 . However, their existence and importance in humans has been met with some scepticism. The contentiousness surrounding this issue partly stems from disparate studies in which γδ T cell numbers and IL-17 expression levels have been widely different. A prime example of this comes from opposing findings in colon cancer studies: one concluding that tumour-infiltrating γδ T cells are highly abundant and a major source of IL-17 (reF.
74
), and another concluding that IL-17-producing γδ T cells are negligible 75 . The contrasting results may be explained by differences between the patient cohorts, such as diet, microbiome, TME and treatment regimen. Ultimately, though, research in this area should be expanded to investigate more patient cohorts, using techniques that examine γδ T cells in situ in addition to ex vivo flow cytometry analysis.
Beyond IL-17, γδ T cells can advance cancer progression via other means (Fig. 3) . One way this can be achieved is through production of IL-4, which can be expressed by both human 78 and mouse 79 γδ T cells. In B16 melanoma, IL-4-producing γδ T cells suppress the killing capacity of other antitumour γδ T cell . Galectin-1-expressing Vγ9 + γδ T cells can also be found infiltrating human ovarian tumours 73 . In subcutaneous and intra-pancreatic mouse models of pancreatic cancer using cell lines derived from Kras G12D ;Trp53
R172H
;Pdx-1-Cre mice, tumour-associated γδ T cells express programmed cell death protein 1 ligand 1 (PDL1) and galectin-9, which promote tumour growth by preventing cytotoxic T cells from killing cancer cells 82 . Like the association of galectin-1 + γδ T cells with ovarian cancer, this observation is relevant to human disease, because PDL1 and galectin-9 expression in circulating and tumour-infiltrating γδ T cells is increased in patients with pancreatic cancer when compared with healthy individuals 82 , although γδ T cell infiltration in this cancer type seems highly variable 83 .
γδ T cells from Kras

G12D
-driven lung tumours express amphiregulin 67 an epidermal growth factor receptor (EGFR) ligand -as well as IL-22 (reFs 67, 84 ), and genetic deletion of IL-22 (reF. 84 ) or preventing IL-22 signalling in lung epithelial cells 67 reduces lung cancer growth.
Regulation of γδ T cell functions
Recruitment of γδ T cells. Mouse IL-17-producing γδ T cells constitutively express the chemokine receptors CC-chemokine receptor 2 (CCR2) and CCR6, which play distinct roles in γδ T cell trafficking. While CCR6 is important for homeostatic circulation of Vγ4 + and Vγ6 + T cells to the dermis, CCR2 drives their recruitment to inflammatory sites, including B16 melanoma lesions 85 . For optimal recruitment of these T cells to inflamed tissues, downregulation of CCR6 is required, which is mediated by the cytokines IL-1β, IL-23 and IL-7, as well as the transcription factors interferon regulatory factor 4 (IRF4) and B cell-activating transcription factor (BATF) 85 .
Intriguingly, Vγ1
+ T cells, which are IFNγ biased (and cytotoxic), also respond to CCR2 and its ligand, CC-chemokine ligand 2 (CCL2) 12 , suggesting a pleiotropic role for this chemokine in γδ T cell responses. In addition, the CCL2-CCR2 axis may influence γδ T cells indirectly, as shown in the K14-Cre;Cdh1
F/F mouse model, where mammary epithelial cells in tumours express high levels of CCL2 that upregulates IL-1β expression in tumour-associated macrophages, which in turn stimulates IL-17 expression in γδ T cells 86 . In humans, whereas Vδ2 + T cells express CCR5 (reF.
87
), tumour-infiltrating Vδ1 + T cells express CXC-chemokine receptor 3 (CXCR3) and are activated by CXCL10 (reF. Regulation of antitumour functions. Cytokines have major effects on γδ T cell functions. IL-2 and IL-15 are the two main cytokines involved in the acquisition of antitumour functions -namely cytotoxicity and IFNγ production (Fig. 2) -by human naive γδ T cell thymocytes 89 as well as γδ T lymphocytes isolated from the peripheral blood of healthy donors 90 or of patients with cancer 91 . Moreover, IL-15-cultured DCs, isolated from healthy donors or patients with cancer, were recently reported to induce, through IL-15 production, the proliferation and expression of cytotoxic molecules and IFNγ in γδ T cells, without concomitant upregulation of inhibitory molecules 92 . Other cytokines, such as IL-12, IL-18 and IL-21, also potentiate the IFNγ production and cytotoxicity of γδ T cells in vitro [93] [94] [95] , while IL-36γ upregulates IFNγ in γδ T cells and slows tumour growth in transplantable melanoma and mammary tumour mouse models 96 . γδ T cells can be negatively impacted by tumourinfiltrating immune cells (Fig. 2) , such as regulatory T cells, via transforming growth factor β (TGFβ) and IL-10, in hepatocellular carcinoma 97 . Circulating neutrophils can also suppress the IFNγ production and cytotoxicity of Vδ2 + T cells in vitro, in an arginase-1-dependent manner 98 or through the production of reactive oxygen species (ROS) 99 . Similarly, myeloid cells can induce γδ T cell exhaustion through PDL1 expression 100 , and the programmed cell death protein 1 (PD1)-PDL1 axis downregulates IFNγ production, cytotoxicity and ADCC [101] [102] [103] . These data suggest that anti-PD1 therapy may enhance γδ T cell functions.
Various cues from the TME, including oxygen tension and nutrient availability, may also regulate antitumour γδ T cell functions. Hypoxia (simulated using 1-2% oxygen) seems to have variable impact on γδ T cell activities in vitro, either promoting them 104 or having no effect 100 when compared to normoxia (20% oxygen). In contrast, low-density lipoprotein-mediated cholesterol uptake by activated human γδ T cells decreased IFNγ production and the expression of NKRs (NKG2D and DNAM-1 (also known as CD226)) in vitro, which translated to diminished antitumour function upon adoptive transfer to a xenograft model of breast cancer 105 . Finally, in the context of cancer treatment, it is relevant to understand how commonly used drugs may impact γδ T cell activity. Low doses of frequently used chemotherapeutic drugs, such as 5-fluorouracil, doxorubicin and cisplatin, sensitize tumour cell lines 106 or colon cancer-initiating cells 107 to Vγ9Vδ2 T cell cytotoxicity. Decitabine, a drug that inhibits DNA methylation, seemingly upregulates NKG2D ligands on osteosarcoma cell lines and enhances their targeting by Vγ9Vδ2 T cells 108 . However, when γδ T cells themselves are subjected to decitabine treatment, their proliferation and cytotoxic features are dampened 109 . The adverse effect of decitabine on γδ T cells occurs through demethylation of the killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) and KIR2DL3 promoter, resulting in increased SP1-mediated expression of KIR2DL2 and KIR2DL3, genes encoding the inhibitory receptors of the KIR family, and in reduced cytotoxic function 109 .
Furthermore, histone deacetylase (HDAC) inhibitors
Thymocytes
Haematopoietic progenitor cells present in the thymus gland.
Oxygen tension
Partial pressure of oxygen molecules dissolved in a liquid (such as blood plasma).
NatUre revIews | CanCer also negatively regulate γδ T cell proliferation and cytotoxic features, although this suppression can be partially reversed by PD1 blockade 110 .
Regulation of pro-tumour functions.
The inflammatory cytokines IL-1β and IL-23, which are often expressed by macrophages 65, 86 or other myeloid cells 59, 67 in the TME, have been widely implicated in promoting IL-17 + γδ T cell responses (Fig. 3) . Blockade or depletion of these cytokines reduced the number of IL-17 + γδ T cells in mouse models of breast cancer 65, 86 , fibrosarcoma 54, 57 and melanoma 55 . More recently, a study in Kras G12D ;Trp53 F/F mice bearing lung tumours demonstrated a role for commensal bacteria in stimulating the production of IL-1β and IL-23 by myeloid cells in a myeloid differentiation primary response 88 (MYD88)-dependent manner. These two cytokines subsequently induced the proliferation and activation of lung IL-17-producing Vγ6 + T cells 67 , consistent with the MYD88-dependent mechanisms driving hepatocellular carcinoma 59 and fibrosarcoma 57 progression. Other pieces of evidence indicate that Toll-like receptor (TLR) pathways are important for inducing IL-1β and IL-23 in cancer-associated myeloid cells upstream of IL-17-producing γδ T cells, as colonic bacteria initiate this pathway in carcinogen-induced and Apc MIN models of colorectal cancer 64, 111 . By contrast, TLR5 negatively regulates IL-17 expression in mammary cancer, ovarian cancer and sarcoma mouse models 73 . The induction of IL-17 expression in γδ T cells seems to be conserved between species, since the combination of IL-1β, IL-23, IL-6 and TGFβ stimulates IL-17 production by human Vδ2 + T cells 71 . Accordingly, human DCs treated with microbial products increase their expression of IL-23, which is sufficient to generate human IL-17-producing γδ T cells 74 . On the basis of these data, IL-1β and IL-23 inhibitors may be useful in abrogating the pro-tumorigenic functions of IL-17-producing γδ T cells in patients with cancer. Support for this inference has been provided by the CANTOS study, a randomized, double-blinded trial involving 10,061 patients across 39 countries for the purpose of preventing cardiovascular events. Unexpectedly, this trial found that an IL-1β antibody (canakinumab) reduced lung cancer incidence and the associated mortality 112 . Since IL-17-producing γδ T cells are abundant in patients with lung cancer 76 , it is tempting to speculate that some of the protective effects of canakinumab may be due to dampening pro-tumour γδ T cell functions. IL-7 is another cytokine that promotes the expansion of both mouse and human IL-17-producing γδ T cells 113 . In the cancer context, we have shown that IL-7 expression in ID8 ovarian tumours correlates with the expansion of IL-17-producing γδ T cells that express the IL-7 receptor 60 . More recently, a study using transplantable mammary tumour models showed that IL-7 expression drives IL-17-producing γδ T cells to potentiate tumour growth and metastasis, and type 1 interferon signalling negatively regulates IL-7 expression. This effect was specific to IL-7, as IL-1β and IL-23 expression was unchanged in tumour-bearing interferon-α receptor 1 (Ifnar1) −/− mice 61 . These data provide another avenue of therapeutic intervention to counteract IL-17 + γδ T cells. Besides cytokines, other molecular cues promoting IL-17 + γδ T cell responses include activation of TCR and NKG2D 54, 114 signalling, as blocking antibodies directed against these two molecules dampen IL-17 production by γδ T cells, both in vitro 54 and in vivo 114 . Additionally, nitric oxide synthase 2 (NOS2), whose expression in γδ T cells is induced by IL-1β and IL-6 (reF.
115
), supports the production of IL-17 while restraining the production of IFNγ 116 . However, since this study employed complete Nos2 −/− mice, it is unclear whether the effect of NOS2 on the γδ T cell phenotype is cell intrinsic or extrinsic. Furthermore, IL-17 + γδ T cell responses are indirectly promoted by cholesterol metabolites that act on neutrophils and enhance γδ T cell-dependent mammary tumour metastasis 117 . By contrast, negative regulators of IL-17 + γδ T cells are still scarce. In a carcinogen-induced colorectal cancer model, the E3 ubiquitin ligase ITCH controls IL-17 expression in γδ T cells, as well as in T helper 17 (T H 17) and innate lymphoid cells, via targeting its master transcription factor, retinoic-acid-receptor-related orphan receptor-γt (RORγt; an immune cell-specific isoform of RORγ), for degradation 118 . In addition, we showed that tumour-associated neutrophils suppress the proliferation of IL-17 + γδ T cells in transplantable hepatocellular carcinoma and melanoma models 119 , consistent with a previous report using a transplantable lung cancer model 120 . We further demonstrated that IL-17 + γδ T cells are especially susceptible to neutrophil-derived ROS, which is associated with their lower level of the key cellular antioxidant glutathione (compared with other lymphocyte subsets) 119 . These findings suggest that mild induction of oxidative stress in the TME may have beneficial effects in tumours highly infiltrated by IL-17 + γδ T cells.
Clinical perspectives and challenges
While most of the data on the interaction of γδ T cells with tumour cells have been obtained in mouse models, as reviewed above, there is clear evidence that γδ T cells impact the progression of human tumours, either as natural immune surveillors or as therapeutic agents. We discuss below the three main lines of research that substantiate this claim: (i) the prognostic value of γδ T cell infiltration in human tumours, (ii) therapeutic proofs of concept using xenograft models of human tumours in immunodeficient mice, and (iii) the promising albeit limited clinical data on their therapeutic modulation. We then summarize the main strategies being pursued to realize the clinical potential of γδ T cells in the near future (Fig. 4) .
Prognostic value in human cancer. Recent data suggest that the dichotomy of IFNγ versus IL-17 expression by γδ T cells in the TME may easily extend from mouse models to human cancer samples from patients. For example, IL-17 + γδ T cells are associated with poor outcomes in patients with gall-bladder 72 and colon 74 cancers. In the latter cancer type, γδ T cells were shown to constitute the major source of IL-17 in tumour www.nature.com/nrc biopsy samples, and IL-17 + γδ T cell infiltration correlated positively with tumour size, invasion, metastasis and overall staging 74 . This contrasts with a subsequent report where patients with colon cancer whose tumour samples were rich in γδ T cells had a significantly longer 5-year disease-free survival rate 75 . Along these lines, other studies scoring either total γδ T cells 121 or, specifically, IFNγ + γδ T cells 72 reported their association with increased patient survival. In fact, the most exhaustive study, by Gentles et al. 122 , on tumour biopsy samples (>18,000 samples from 39 cancer types), analysed at the transcriptomic level, ranked γδ T cells as the number 1 (out of 22) immune cell population associated with favourable prognosis, even though the bioinformatics analysis of these data has subsequently been contested, due to the inability to distinguish a γδ T cell signature from a CD4 + T cell, CD8 + T cell or NK cell signature 123 . It is interesting to note that, unlike mouse γδ T cells, circulating human γδ T cells are highly biased towards IFNγ production (often co-expressed with TNF) 89, 124 , which suggests that tumour-associated inflammation may be the driver of IL-17 + γδ T cell differentiation 3 . This is consistent with what has been reported in the infection setting -for example, in bacterial meningitis, where a large proportion of IL-17 + γδ T cells are found in the cerebrospinal fluid 71 . As with mouse γδ T cells, IL-1β, IL-23 and TGFβ seem to be the main drivers of human IL-17 + γδ T cell differentiation 70, 71 . Besides IL-17 production, the adoption of suppressive functions that interfere with DC maturation and functions has been proposed as a pro-tumour role of human γδ T cells 88, [125] [126] [127] . In particular, an immunohistochemistry examination of breast cancer primary specimens revealed high infiltration by γδ T cells, which correlated positively with advanced tumour stages and lymph node metastasis, and negatively with patient survival 126 .
More recently, γδ T cells infiltrating human pancreatic ductal adenocarcinoma (PDAC; which were ~40% of all tumour-infiltrating lymphocytes (TILs) in one study 82 and <5% of TILs in another 83 ) were shown to express the potent immunosuppressive ligand PDL1; in another study, γδ T cells suppressed CD4 + and CD8 + T cell infiltration and functionality in a mouse model of PDAC 82 . It remains unclear whether abundant PDL1 expression by γδ T cells is exclusive to the pancreatic cancer microenvironment or shared among other tumour types. Future research should formally link such functional properties as IFNγ, IL-17 or PDL1 expression to the analysis of γδ T cells in human cancer biopsy samples. This will be important for validating the findings of Gentles et al., which at face value suggest that the antitumour functions of γδ T cells dominate over their pro-tumour properties in the vast majority of human cancers 122 .
Current strategies to bring γδ T cells to the clinic. All the available clinical experience with γδ T cells derives from the modulation of polyclonal Vγ9Vδ2 T cell activities, based on either in vivo stimulation with aminobisphosphonates or adoptive cell transfer following in vitro activation and expansion with aminobisphosphonates or synthetic phosphoantigens. The rationale is derived from the unique TCR-dependent reactivity of Vγ9Vδ2 T cells to non-peptidic pyrophosphates (known as phosphoantigens), which can be increased therapeutically upon aminobisphosphonate (zoledronate or pamidronate) administration. Given the upregulation of the mevalonate pathway (which produces the pyrophosphate intermediates) in cancer cells, activated Vγ9Vδ2 T cells are expected to efficiently and selectively target tumour cells. Despite the confirmed safety with this strategy and some interesting responses [128] [129] [130] , the cumulative clinical results have been largely disappointing, given the low objective response rates obtained in both settings 131 . Various reasons have been put forward to explain the therapeutic failures, including a highly variable capacity of the polyclonal Vγ9Vδ2 TCR repertoire to recognize tumours, and the functional instability, dysfunction or exhaustion of chronically activated Vγ9Vδ2 T cells. Critically, new strategies have emerged to tackle the previous limitations, thus creating a renewed momentum in the clinical application of γδ T cells -reinvigorating interest in Vγ9Vδ2 T cells but also drawing attention to their Vδ1 + T cell counterparts (Fig. 4) . Combinations with antibodies neutralizing inhibitory cytokines (such as TGFβ or IL-10) or with immune checkpoint inhibitors targeting PD1 or cytotoxic T lymphocyte antigen 4 (CTLA4) are logical approaches to counteract immune suppression (and exhaustion) in vivo. In fact, in patients with melanoma treated with ipilimumab (anti-CTLA4), higher frequencies of Vδ2 + (but not Vδ1 + ) T cells constituted an independent indicator of improved overall survival 132 . Future studies in various cancer types should give more attention to these aspects of anti-PD1 and anti-CTLA4 therapy, since recent work using MCA-induced sarcomas in mice suggests that γδ T cell infiltration and phenotype change very little after anti-PD1 and anti-CTLA4 therapy 133 . Another way to counteract potential dysfunction of patient-derived Vγ9Vδ2 T cells (either ex vivo or induced by long-term in vitro culture) using combination approaches is the co-activation with autologous moDCs or addition of the tyrosine kinase inhibitor ibrutinib (approved for chronic lymphocytic leukaemia (CLL) treatment) 134 . Ibrutinib has direct effects on Vγ9Vδ2 T cells, as it binds to IL-2-inducible T cell kinase (ITK) and promotes an antitumour IFNγ-producing phenotype 134 . Finally, bispecific antibodies are also being developed as a means to enhance Vγ9Vδ2 T cell activation and targeting at the tumour site. A nanobody-based construct targeting both Vγ9Vδ2 T cells and EGFR has induced potent Vγ9Vδ2 T cell activation and tumour cell killing both in vitro and in vivo (in a xenograft model of colon cancer) 135 . Moreover, a [(HER2) 2 xCD16] triplebody molecule, which re-directed CD16-expressing γδ T cells and NK cells to the tumour-associated cell surface antigen HER2, showed augmented cytotoxicity (and superiority to trastuzumab) against HER2-expressing PDAC as well as breast and ovarian tumour cells 136 . A different strategy under clinical development to overcome the low persistence or impaired activation status of Vγ9Vδ2 T cells in patients with advanced cancer is the transduction of selected high-affinity Vγ9Vδ2 TCRs 137 into αβ T cells that (under particular settings, including immune checkpoint inhibition) are expected to develop durable, memory-based responses. These hybrid T cells, named T cells engineered with defined gamma delta TCRs (TEGs), have been shown to endow highly polyclonal αβ T cells with innate-like responsiveness against multiple tumours, based on the broad reactivity of Vγ9Vδ2 TCRs 138 . The TEG cellular product has already been produced under good manufacturing practice (GMP) conditions 139 and is now being tested in a phase I clinical trial in patients with haematological malignancies 140 (NTR 6541). Besides the renewed interest in Vγ9Vδ2 T cells and their receptors, there has been more recent exploration of a Vδ1 + T cell avenue in cancer immunotherapy (Fig. 4) . Although there are still no validated agonist Vδ1 + TCR antibodies that could potentially be employed to activate Vδ1 + T cells in vivo, their use in adoptive cell therapy has been made possible owing to methodological breakthroughs in their in vitro expansion, upon isolation from human epithelial tissues 141 or peripheral blood 142 .
In particular, we have developed a 3-week clinical-grade protocol involving TCR and cytokine stimulation that allows >1,000-fold large-scale expansion of Vδ1 + T cells, which thereby increases Vδ1 + T cells from <0.5% of all peripheral blood lymphocytes to >70% of the cellular product (the remaining cells being mostly other γδ T cell subsets); these have been termed Delta One T (DOT) cells 142 . Importantly, TCR-mediated activation in the presence of IL-15 induces de novo expression of NKRs, particularly NKp30 and NKp44, that enhance the capacity of DOT cells to target multiple haematological 90, 142, 143 and solid tumour (B.S-S., unpublished observations) types in vitro. DOT cells did not show any reactivity against normal cell types (including multiple leukocyte subsets and activated lymphocytes, as well as healthy fibroblasts) that have been tested. Antibody blockade and genetic interference (CRISPR) experiments suggest that DOT cells combine TCR-mediated and NKR-mediated mechanisms in tumour cell recognition 90, 142, 143 . A recent paper showed that Vδ1 + cells generated from haematopoietic stem and/or progenitor cells in vitro can recognize the two melanoma-associated antigens melanoma antigen recognized by T cells 1 (MART1) and gp100 (also known as melanocyte protein PMEL) 144 . Challenging decades of research, the study showed that MART1-and gp100-reactive γδ TCRs bind human leukocyte antigen A2 (HLA-A2), identifying an MHCrestricted γδ TCR for the first time. While evidence for the existence of these cells in human tumours was not provided, the data open up new possibilities for γδ T cell-based adoptive cell therapies.
Finally, chimeric antigen receptors (CARs) are an obvious addition to the γδ T cell-based cancer immunotherapy portfolio 145 . By combining antibody-like high-affinity antigen recognition with T cell signalling, CARs have been shown to dramatically increase the potency of adoptive T cell products 146, 147 , leading to their approval for treatment of refractory B cell malignancies 148 . Activated γδ T cells are amenable to CAR transduction and may have the added advantage of broadly reactive γδ TCRs in tackling potential immune evasion of the specific CAR antigen, which has been observed in the clinic 149, 150 . Whether CAR-transduced γδ T cells will also be beneficial in terms of minimizing the cytokine release syndrome and neurotoxicity adverse events associated with conventional CAR T cells remains to be investigated. Indeed, it will also be key to compare www.nature.com/nrc their relative persistence in vivo and, ultimately, their efficacy in inducing cancer elimination.
Therapeutic proof of concept and challenges.
Although mice (including γδ T cell-deficient mice) have been instrumental in revealing the non-redundant roles played by γδ T cells in cancer development and progression, evolutionary divergence in the TCRγ and TCRδ genes between rodents and primates 6 makes syngeneic models poorly suited to provide proof of concept for γδ T cell-based cancer immunotherapies. In particular, Vγ9Vδ2 and Vδ1 + T cells, the two main human γδ T cell subsets, do not have orthologues or equivalents in mice, and the strong reactivity of Vγ9Vδ2 T cells to non-peptidic phosphoantigens (either tumour-derived or synthetic) is not conserved in rodents 3 . Preclinical in vivo proof-of-concept studies have been performed mostly in xenograft models using human tumour cell lines or primary samples in immuno deficient (such as NSG) mice. Thus, Vγ9Vδ2 T cells have been administered (usually together with IL-2) to multiple mouse models after in vitro expansion with amino bisphosphonates or pyrophosphates and been shown to impact tumour load and progression. To name some interesting examples, a single dose of Vγ9Vδ2 T cells had a striking impact on tumour burden in a spontaneous and highly immunosuppressive (via PD1 and CTLA4) Epstein-Barr virus-driven lymphoma model 151 ; a nanobody-based construct targeting both Vγ9Vδ2 T cells and EGFR has induced potent Vγ9Vδ2 T cell activation and tumour cell killing in a xenograft model of human colon cancer 135 ; and the stereotaxic administration of Vγ9Vδ2 T cells in an orthotopic model of glioblastoma led to tumour cell elimination and to much improved host survival 152 . Of note, therapeutic success in the latter model required the co-administration of zoledronate with the Vγ9Vδ2 T cells, thus highlighting the importance of 'sensitizing' tumours (by increasing intra-tumoural phosphoantigen concentrations) to Vγ9Vδ2 T cells. Likewise, the TEG approach -that is, αβ T cells transduced with high-affinity Vγ9Vδ2 TCRs -has also been successfully tested in a lymphoma xenograft model 137 .
Vδ1
+ T cells have also shown substantial in vivo efficacy in preclinical models of human cancer. In fact, in one of very few studies in which the in vivo potency of Vδ1 + T cells was compared with that of their Vδ2 + counterparts, both of which were expanded with artificial antigen-presenting cells (derived from K562 CML cells) serving as irradiated feeders, it was observed that Vδ1 + T cells had superior therapeutic activity, as evaluated by improved host (NSG mouse) survival to injected human CAOV3 ovarian cancer cells 153 . We subsequently tested Vδ1 + T cells expanded and differentiated with the DOT protocol in four xenograft models of leukaemia (acute myeloid leukaemia or CLL) 142, 143 . In all the models, DOT-cell treatment diminished tumour burden and prolonged host survival, and moreover prevented systemic tumour dissemination in the MEC-1 CLL xenograft 142 . Besides efficacy, safety (toxicology) is clearly a key component of (pre)clinical studies. However, this constitutes a major challenge and intrinsic limitation of xenograft models. For example, although DOT cell administration did not produce any histological alterations in tissues or in biochemical analyses reporting liver and kidney function, the host tissue cells were mouse, and therefore lacked potentially relevant human self-antigens that would allow evaluation of toxic side effects. An alternative, albeit a very expensive one, is the use of non-human primates, which have been shown to induce potent Vγ9Vδ2 T cell responses in vivo 154, 155 . The latter advantage notwithstanding, non-human primates also present various limitations as toxicology models: (i) in the setting where macaque-derived T cells are administered to macaques, the cellular product being tested may be considerably different (in terms of phenotype and functionality) from the human counterpart to be used in the clinic; (ii) if injecting the human cellular product into macaques, there are issues with the potential need for immune suppression (to prevent graft rejection); and (iii) tumour challenge, which may be required so as to mimic the relevant cellular interactions and even to sustain γδ T cell activation in vivo, involves ethical issues.
Given the limitations of in vivo models, we believe the preclinical therapeutic potential of antitumorigenic human γδ T cells is best evaluated by detailed in vitro assessment of tumour versus healthy cell targeting, using comprehensive collections of primary tumour samples and normal cell types of multiple origins (for example, haematopoietic, epithelial, and endothelial), ahead of regulatory discussions and, ultimately, of clinical trials.
Conclusions
As a result of almost two decades of translational and clinical research on γδ T cells in cancer, the time is ripe for developing efficacious therapies based on their in vivo activation or upon adoptive cell transfer. The limited success of previous clinical tests with Vγ9Vδ2 T cells may now be overcome by innovative strategies aiming to surmount exhaustion and guarantee persistence and improved tumour cell recognition. At the same time, we now have the means to expand their rarer (in the blood) Vδ1 + T cell counterparts, which have high tropism for tissues, including tumours, and we can therefore test them in the clinic for the first time. These are exciting times for γδ T cell application in cancer immuno therapy, as decisive clinical trials will take place in the next couple of years.
One important conclusion arising from the initial modulation of Vγ9Vδ2 T cells in patients with cancer is the overall safety of such strategies in the autologous setting 131 . But a much more ambitious and potentially feasible goal is the development of allogeneic, off-theshelf γδ T cell-based immunotherapies. γδ T cells are especially suited for allogeneic strategies, since they are largely not restricted by MHC, thus avoiding the graft-versus-host effects of MHC-mismatched αβ T cells. In fact, γδ T cell (and particularly Vδ1 + T cell) reconstitution and persistence in patients with leukaemia who received partially mismatched but related donor bone marrow transplantations were the best predictors of long-term disease-free survival 156 , and this has promoted the successful application of haploidentical stem cell transplantation using αβ T cell-depleted and
Stereotaxic administration
Delivery of a compound into the brain using an external, three-dimensional frame of reference, usually based on the Cartesian coordinate system.
Haploidentical stem cell transplantation
Treatment of blood disorders involving the replacement of the patient's haematopoietic cells by healthy partially (50%) human leukocyte antigenmatched haematopoietic progenitors.
NatUre revIews | CanCer B cell-depleted grafts 157 . One interesting prospect of allogeneic γδ T cell immunotherapies is using them to treat aggressive haematological tumours derived from the transformation of γδ T cells themselves (Box 2).
Because they are not restricted by MHC, most γδ T cells also bypass one of the most common cancer immune evasion mechanisms, the downregulation of surface MHC class I molecules 158 . However, since they do not recognize mutated peptides, γδ T cells might be especially suited for treating tumours with low mutational burdens, where immune checkpoint inhibition is notably unsuccessful 159 . On the basis of ample evidence from preclinical models, the balance between IFNγ-versus IL-17-producing γδ T cells in the TME may strongly impact on the success of their therapeutic modulation. Thus, upcoming clinical trials should track such activities while clearly attempting to promote IFNγ-over IL-17-producing γδ T cells in vivo. This might require specific cytokine signals, such as IL-15, that epigenetically 'lock' γδ T cells in an IFNγ-producing programme; such complements can be provided during the in vitro expansion and differentiation of cellular products, or administered in vivo to patients with cancer, which would require formal testing in the clinic. Another important factor to consider is the impact of the microbiome, since at least in the mouse lung it has been shown to drive the expansion of tumour-promoting IL-17 + γδ T cells 67, 160 . Finally, the prognostic value of tumour-infiltrating γδ T cells should be revisited in multiple cancer types with the resolution of IFNγ versus IL-17 protein expression by γδ T cells.
From a more fundamental standpoint, future research should address the non-IL-17-mediated pro-tumorigenic functions of γδ T cells and focus on further dissecting the key cellular partners and molecular co-receptors that may regulate γδ T cell activities in the TME. Finally, the identification of tumour antigens that are recognized by γδ T cells, through either TCRs or NKRs, remains a priority 14 : it will help clarify the non-redundant role of γδ T cells in immune surveillance of tumours and might be the key for rational selection of the patients to be treated with γδ T cell-based cancer immunotherapies.
Published online 17 June 2019
Box 2 | When γδ T cells become malignant γδ T cell lymphomas are aggressive and rare haematological malignancies that develop from the transformation of mature γδ T cells and include hepatosplenic γδ T cell lymphoma (HSGDTL) and primary cutaneous γδ T cell lymphoma (PCGDTL). HSGDTL, which is more common among young males, presents with splenomegaly (abnormally enlarged spleen) and thrombocytopenia (a low blood platelet count), often in the absence of nodal involvement; it progresses rapidly, responds poorly to treatment and is associated with high mortality 162 . PCGDTL represents less than 1% of all primary cutaneous lymphomas but is highly aggressive and deadly 163 . γδ T cell acute lymphoblastic leukaemia (γδ T-ALL) derives from the transformation of immature γδ thymocytes and presents with clinical features distinct from αβ T-ALL 164 . Albeit rare, γδ T-ALL accounts for up to 10% of all T-ALL cases, which is substantially higher than the proportion (around 1%) of γδ thymocytes among the total number of thymocytes in the human thymus, thus raising the possibility that γδ thymocytes have increased potential for malignant transformation 164, 165 .
